메뉴 건너뛰기




Volumn 44, Issue 11, 2005, Pages 1165-1177

Single-dose clinical pharmacokinetic studies of gefitinib

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

EID: 26944478585     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200544110-00004     Document Type: Article
Times cited : (137)

References (25)
  • 1
    • 0033063774 scopus 로고    scopus 로고
    • The epidermal growth factor receptor and its inhibition in cancer therapy
    • Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241-50
    • (1999) Pharmacol Ther , vol.82 , pp. 241-250
    • Woodburn, J.R.1
  • 2
    • 0028955388 scopus 로고
    • Epidermal growth factor-related peptides and their receptors in human malignancies
    • Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232
    • (1995) Crit Rev Oncol Hematol , vol.19 , pp. 183-232
    • Salomon, D.S.1    Brandt, R.2    Ciardiello, F.3
  • 3
    • 0032999409 scopus 로고    scopus 로고
    • Molecules in focus: EGF receptor
    • Wells A. Molecules in focus: EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-43
    • (1999) Int J Biochem Cell Biol , vol.31 , pp. 637-643
    • Wells, A.1
  • 4
    • 0034093597 scopus 로고    scopus 로고
    • Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells
    • Chen Z, Ke LD, Yuan XH, et al. Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells. Anticancer Res 2000; 20: 899-902
    • (2000) Anticancer Res , vol.20 , pp. 899-902
    • Chen, Z.1    Ke, L.D.2    Yuan, X.H.3
  • 5
    • 0031107250 scopus 로고    scopus 로고
    • The epidermal growth factor receptor in breast cancer
    • Fox SB, Harris AL. The epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 1997; 2: 131-41
    • (1997) J Mammary Gland Biol Neoplasia , vol.2 , pp. 131-141
    • Fox, S.B.1    Harris, A.L.2
  • 6
    • 0035939330 scopus 로고    scopus 로고
    • Studies leading to the identification of ZD1839 (IRESSA™): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
    • Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (IRESSA™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001; 11: 1911-4
    • (2001) Bioorg Med Chem Lett , vol.11 , pp. 1911-1914
    • Barker, A.J.1    Gibson, K.H.2    Grundy, W.3
  • 7
    • 0141568003 scopus 로고    scopus 로고
    • The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index
    • She Y, Lee F, Chen J, et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res 2003; 9: 3773-8
    • (2003) Clin Cancer Res , vol.9 , pp. 3773-3778
    • She, Y.1    Lee, F.2    Chen, J.3
  • 8
    • 0034489914 scopus 로고    scopus 로고
    • Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
    • Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885-92
    • (2000) Clin Cancer Res , vol.6 , pp. 4885-4892
    • Sirotnak, F.M.1    Zakowski, M.F.2    Miller, V.A.3
  • 9
    • 0012381722 scopus 로고    scopus 로고
    • Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
    • Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-46
    • (2003) J Clin Oncol , vol.21 , pp. 2237-2246
    • Fukuoka, M.1    Yano, S.2    Giaccone, G.3
  • 10
    • 0142055937 scopus 로고    scopus 로고
    • Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial
    • Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-58
    • (2003) JAMA , vol.290 , pp. 2149-2158
    • Kris, M.G.1    Natale, R.B.2    Herbst, R.S.3
  • 11
    • 12144287534 scopus 로고    scopus 로고
    • United States FDA drug approval summary: Gefitinib (ZD1839; Iressa) tablets
    • Cohen MH, Williams GA, Sridhara R, et al. United States FDA drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10: 1212-8
    • (2004) Clin Cancer Res , vol.10 , pp. 1212-1218
    • Cohen, M.H.1    Williams, G.A.2    Sridhara, R.3
  • 12
    • 0035023187 scopus 로고    scopus 로고
    • Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers
    • Swaisland H, Laight A, Stafford L, et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001; 40: 297-306
    • (2001) Clin Pharmacokinet , vol.40 , pp. 297-306
    • Swaisland, H.1    Laight, A.2    Stafford, L.3
  • 13
    • 0037673681 scopus 로고    scopus 로고
    • Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors
    • Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003; 14: 922-30
    • (2003) Ann Oncol , vol.14 , pp. 922-930
    • Nakagawa, K.1    Tamura, T.2    Negoro, S.3
  • 14
    • 0036569870 scopus 로고    scopus 로고
    • ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
    • Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20: 2240-50
    • (2002) J Clin Oncol , vol.20 , pp. 2240-2250
    • Ranson, M.1    Hammond, L.A.2    Ferry, D.3
  • 15
    • 0036842170 scopus 로고    scopus 로고
    • Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
    • Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292-302
    • (2002) J Clin Oncol , vol.20 , pp. 4292-4302
    • Baselga, J.1    Rischin, D.2    Ranson, M.3
  • 16
    • 0037106377 scopus 로고    scopus 로고
    • Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial
    • Herbst RS, Maddox A-M, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20: 3815-25
    • (2002) J Clin Oncol , vol.20 , pp. 3815-3825
    • Herbst, R.S.1    Maddox, A.-M.2    Rothenberg, M.L.3
  • 17
    • 0037142314 scopus 로고    scopus 로고
    • A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: Validation and use in phase I clinical trials
    • Jones HK, Stafford LE, Swaisland HC, et al. A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in phase I clinical trials. J Pharm Biomed Anal 2002; 29: 221-8
    • (2002) J Pharm Biomed Anal , vol.29 , pp. 221-228
    • Jones, H.K.1    Stafford, L.E.2    Swaisland, H.C.3
  • 19
    • 10644261348 scopus 로고    scopus 로고
    • Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor in rat, dog and man
    • McKillop D, Hutchison M, Partridge EA, et al. Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor in rat, dog and man. Xenobiotica 2004; 34: 917-34
    • (2004) Xenobiotica , vol.34 , pp. 917-934
    • McKillop, D.1    Hutchison, M.2    Partridge, E.A.3
  • 20
    • 0037109014 scopus 로고    scopus 로고
    • ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signalling with potential for cancer therapy
    • Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signalling with potential for cancer therapy. Cancer Res 2002; 62: 5749-54
    • (2002) Cancer Res , vol.62 , pp. 5749-5754
    • Wakeling, A.E.1    Guy, S.P.2    Woodburn, J.R.3
  • 21
    • 25144436285 scopus 로고    scopus 로고
    • Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol
    • Swaisland HC, Ranson M, Smith RP, et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet 2005; 44 (10): 1067-81
    • (2005) Clin Pharmacokinet , vol.44 , Issue.10 , pp. 1067-1081
    • Swaisland, H.C.1    Ranson, M.2    Smith, R.P.3
  • 22
    • 0026542525 scopus 로고
    • Relative expression of cytochrome P450 isozymes in human liver and association with the metabolism of drugs and xenobiotics
    • Forrester LM, Henderson TJ, Glancey MJ, et al. Relative expression of cytochrome P450 isozymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 1992; 281: 359-68
    • (1992) Biochem J , vol.281 , pp. 359-368
    • Forrester, L.M.1    Henderson, T.J.2    Glancey, M.J.3
  • 23
    • 26944478042 scopus 로고    scopus 로고
    • The distribution of gefitinib ('Iressa', ZD1839) into mouse xenograft tumours [poster]. Nov 17-21; Boston (MA)
    • McKillop D, Stephens TC, Partridge EA, et al. The distribution of gefitinib ('Iressa', ZD1839) into mouse xenograft tumours [poster]. 15th AACR-NCI-EORTC Symposium; 2003 Nov 17-21; Boston (MA)
    • (2003) 15th AACR-NCI-EORTC Symposium
    • McKillop, D.1    Stephens, T.C.2    Partridge, E.A.3
  • 24
    • 0022966980 scopus 로고
    • Comparison of canine and human gastrointestinal physiology
    • Dressman JB. Comparison of canine and human gastrointestinal physiology. Pharm Res 1986; 3: 123-31
    • (1986) Pharm Res , vol.3 , pp. 123-131
    • Dressman, J.B.1
  • 25
    • 0033805179 scopus 로고    scopus 로고
    • In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs
    • Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci 2000; 11 Suppl. 2: S73-80
    • (2000) Eur J Pharm Sci , vol.11 , Issue.2 SUPPL.
    • Dressman, J.B.1    Reppas, C.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.